Skip to main content
Best News Website or Mobile Service
 
WAN-IFRA Digital Media Awards Worldwide
Best News Website or Mobile Service
 
Digital Media Awards Worldwide
Hamburger Menu

Advertisement

Advertisement

World

US authorises Moderna, Pfizer-BioNTech COVID-19 vaccine boosters retooled for Omicron

US authorises Moderna, Pfizer-BioNTech COVID-19 vaccine boosters retooled for Omicron

Vials with Pfizer-BioNTech and Moderna COVID-19 vaccine labels are seen in this illustration on Mar 19, 2021. (Illustration: Reuters/Dado Ruvic)

The US Food and Drug Administration on Wednesday (Aug 31) authorised the retooled COVID-19 booster shots of both Moderna and Pfizer-BioNTech that target the currently dominant BA.4 and BA.5 Omicron subvariants of the coronavirus.

Both vaccines also include the original version of the virus targeted by all the previous COVID-19 shots as the country prepares for another vaccination campaign in the fall season.

As a single dose, Moderna's vaccine is authorised for those aged 18 and above, while Pfizer's bivalent candidate is for those aged 12 and above.

The US government has purchased 175 million doses of the booster shots in an effort to stave off the worst effects of a potential surge in new infections as schools reconvene and people spend more time indoors as the weather grows colder.

The FDA in June asked vaccine makers to tailor shots to the two subvariants responsible for the most recent surge in infections worldwide. The BA.5 subvariant currently accounts for more than 88 per cent of US infections.

The US Centers for Disease Control and Prevention's vaccine advisory panel is scheduled to meet on Thursday to make recommendations for use of the redesigned shots that Director Rochelle Walensky will take into consideration before making a final decision.

BOOKMARK THIS: Our comprehensive coverage of the COVID-19 pandemic and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus pandemic: https://cna.asia/telegram

Source: Reuters/rj

Advertisement

Also worth reading

Advertisement